Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy

References

• IDFInternational Diabetes Federation: IDF Diabetes Atlas7th edBrusselsInternational Diabetes Federation2013 Available from: www.diabetesaltlas.orgAccessed September 20, 2016
   Google Scholar
• Epicentro [webpage on the Internet]La patologia diabetica: dati di prevalenza a livello Nazionale. 2015. [Diabetes: prevalence data at the Italian national level] Available from: http://www.epicentro.iss.it/igea/diabete/prevalenza.aspAccessed September 20, 2016
   Google Scholar
• PaganoEDe RosaMRossiEThe relative burden of diabetes complications on healthcare costs: the population-based CINECA-SID ARNO diabetes observatoryNutr Metab Cardiovasc Dis2016261094495027289165
   PubMed Web of Science ®Google Scholar
• RavasioRAnalisi di costo-efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo 2 in fallimento secondario al doppio ipoglicemizzante orale. [Cost-effectiveness analysis of exenatide versus glargine insulin in the treatment of type II diabetic patients failing double hypoglycemic oral therapy]G Ital Health Technol Assess2008112130 Italian
   Google Scholar
• MarcellusiAVitiRMecozziAMenninniFSThe direct and indirect cost of diabetes in Italy: a prevalence probabilistic approachEur J Health Econ201417213914725427540
   PubMed Web of Science ®Google Scholar
• AMD Associazione dei Medici Diabetologi – [SID] Società Italiana di DiabetologiaStandard italiani per la cura del diabete mellito. 2016. [AMD Italian Association of Clinical Diabetologists - SID Italian Diabetes Society. Italian standard for diabetes mellitus 2016] Available from: http://www.standarditaliani.it/skin/www.standarditaliani.it/pdf/STANDARD_2016_June20.pdfAccessed February 8, 2017 Italian
   Google Scholar
• KrobotKFerranteSADaviesMJLower risk of hypoglicemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1c valueCurr Med Res Opin20122881281128722697277
   PubMed Web of Science ®Google Scholar
• FerranniniEFonsecaVZinmanBFifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes Obes Metab200911215716619125777
   PubMed Web of Science ®Google Scholar
• KaragiannisTPaschosPPaletasKMatthewsDTsapasADipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysisBMJ2012344e136922411919
   PubMed Web of Science ®Google Scholar
• [SID] Società Italiana di DiabetologiaIl diabete in Italia [SID Italian Diabetes Society Diabetes in Italy]Bologna, ItalyBononia University Press2016 Italian
   Google Scholar
• ValensiPde PouvourvilleGBenardNTreatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational studyDiabetes Metab201541323123825976701
   PubMed Web of Science ®Google Scholar
• HusereauDDrummondMPetrouSISPOR Health Economic and Evaluation Publication Guidelines- CHEERS Good Reporting Practices Task ForceConsolidated health economic evaluation reporting standards (CHEERS)-explanation and evaluation: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task forceValue Health201316223125023538175
   PubMed Web of Science ®Google Scholar
• ArechavaletaRSeckTChenYEfficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trialDiabetes Obes Metab201113216016821199268
   PubMed Web of Science ®Google Scholar
• MonamiMGenoveseSMannucciECardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trialsDiabetes Obes Metab2013151093895323594109
   PubMed Web of Science ®Google Scholar
• PiroloRBettiolABolcatoJCost-of-illness study of diabetes mellitus: focus on patients with type 2 diabetesGRHTA2016313241
   Google Scholar
• Degli EspostiLSaragoniSBudaSDegli EspostiEClinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patientsClinicoecon Outcomes Res2014646347225364266
   PubMedGoogle Scholar
• SreenanSAndersenMThrstedBLWoldenMLEvansMIncreased risk of severe hypoglycemic events with increasing frequency of non-severe hypoglycemic events in patients with type 1 and type 2 diabetesDiabetes Ther20145244745825023521
   PubMed Web of Science ®Google Scholar
• LeeseGPWangJBroomhallJDARTS/MEMO CollaborationFrequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource useDiabetes Care20032441176011780
   Google Scholar
• AIFA [webpage on the Internet]Italian Medicines Agency2016 Available from: http://www.agenziafarmaco.gov.it/content/liste-di-trasparenza-e-rimborsabilitaAccessed September 20, 2016
   Google Scholar
• Italian Ministry of Health [webpage on the Internet]Italian National Tariffs2013 Available from: http://www.gazzettaufficiale.it/eli/id/2013/01/28/13A00528/sgAccessed September 20, 2016
   Google Scholar
• NicolucciAL’ipoglicemia: le varie dimensioni del problema in ItaliaG AMD201417suppl 359
   Google Scholar
• MannocciAMaroccoAGualanoMRCapriSLa TorreGRicciardiWConsumo di risorse e costi associati al trattamento delle patologie sostenute da Streptococcus pneumoniae (Spn) ed Haemophilus influenzae non tipizzabile (NTHi). [Resource use and costs associated with the treatment of Streptococcus pneumoniae (Spn) and Haemophilus influenzae non-typable (NTHi)]Ital J Public Health20096suppl 5S20S33 Italian
   Google Scholar
• MonesiGDalla epidemiologia clinica alle strategie assistenziali. Uso e lettura dei dati amministrativi. Presentazione a CONVEGNO “La malattia diabetica in Veneto dal 1997 al 2002. Dalla Epidemiologia Clinica alle Stategie Assistenziali. [From clinical epidemiology to strategy for care. Use of administrative data. Congress presentation “Diabetic disease in Veneto 1997–2002. From Clinical Epidemiology to Strategies for Assistence]RovigoCittadella SocioSanitaria2005 Italian
   Google Scholar
• BertoPInzatariDScrutinioDClopidogrel idrogenosolfato versus aspirina nella riduzione degli eventi aterotrombotici nelle popolazioni a elevato rischio cardiovascolare: un’analisi italiana di costo-efficacia basata sul trial CAPRIE. [Clopidogrel hydrogen sulphate versus aspirin in the reduction of atherothrombotic events in high cardiovascular risk populations: an Italian cost-effectiveness analysis based on the CAPRIE trial]Pharmacoeconomics Ital Res Articles20101213350 Italian
   Google Scholar
• FattoreGTorbicaASusiAThe social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness studyBMC Neurol20121213723150894
   PubMed Web of Science ®Google Scholar
• LucioniCGaranciniMPMassi-BenedettiMIl costo sociale del diabete di tipo 2 in Italia: lo studio CODE-2. [Cost of illness of type II diabetes in Italy: the CODE-2 study]Pharmacoeconomics Ital Res Articles200021121 Italian
   Google Scholar
• Rapporto annuale sull’attività di ricovero ospedaliero SDO. [Annual report on hospital admissions in Italy]Dati SDO 2012RomeItalian Ministry of Health2013 Italian
   Google Scholar
• Origin Trial investigatorsGersteinHCBoschJBasal insulin and cardiovascular and other outcomes in dysglycemiaN Engl J Med2012367431932822686416
   PubMed Web of Science ®Google Scholar
• Indagine Multiscopo sulle famiglie: aspetti della vita quotidiana [webpage on the Internet]. [Multiscope survey on families: aspects of everyday life]Elaborazione File Microdati AnnoItalian Institute of Statistics (ISTAT)2013 Available from: https://www.istat.it/it/archivio/microdati+ad+uso+pubblico+storiciAccessed July 13, 2016 Italian
   Google Scholar
• JonssonLBolinderBLundkvistJCost of hypoglycemia in patients with type 2 diabetes in SwedenValue Health20069319319816689714
   PubMed Web of Science ®Google Scholar
• BrodMChristensenTThomsenTLBushnellDMThe impact of non-severe hypoglycemic events on work productivity and diabetes managementValue Health201114566567121839404
   PubMed Web of Science ®Google Scholar
• Giorni-Lavorativi [database on the Internet]Working Days and Public Holidays by Contry2017 Available from: http://www.giorni-lavorativi.com/EN/giorni-lavorativi_festivi_2014.htmAccessed February 8, 2017
   Google Scholar
• EUROSTAT European Statistics [database on the Internet]Gross Domestic Product at Market Prices2013 Available from: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=en&pcode=tec00001Accessed February 8, 2017
   Google Scholar
• L’uso dei farmaci in Italia- Rapporto OsMed 2016. [The medicines utilization monitoring centre. national report on medicines use in Italy 2016]RomeItalian Medicine Agency, AIFA2017 Italian
   Google Scholar
• Thales GroupMarket research on Thales database 2nd Quarter2016
   Google Scholar
• EPICENTROLa patologia diabetica: dati di prevalenza a livello nazionale. 2017. [Diabetes: prevalence dataA at italian national level] Available from: http://www.epicentro.iss.it/igea/diabete/prevalenza.aspAccessed February 8, 2017 Italian
   Google Scholar
• ShinSKimHThe effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort studyTher Clin Risk Manag20161243544427042085
   PubMed Web of Science ®Google Scholar
• GreenJBBethelMAArmstrongPWTECOS Study GroupEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
   PubMed Web of Science ®Google Scholar
• MonamiMAhrénBDicembriniIMannucciEDipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trialsDiabetes Obes Metab201315211212022925682
   PubMed Web of Science ®Google Scholar
• ErikssonJSBodegardJNathansonDSulphonylurea compared to DPP4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortalityDiabetes Res Clin Pract2016117394727329021
   PubMed Web of Science ®Google Scholar
• NyströmTBodegardJNathansonDThuressonMNorhammarAErikssonJWSecond line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemiaDiabetes Res Clin Pract201712319920828056431
   PubMed Web of Science ®Google Scholar
• FadiniGPAvogaroADegli EspostiLOsMed Health-DB NetworkRisk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB DatabaseEur Heart J201536362454246226112890
   PubMed Web of Science ®Google Scholar
• InzucchiSETunceliKQiuYProgression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapyDiabetes Obes Metab2015171095696425962401
   PubMed Web of Science ®Google Scholar